PATHWORK DIAGNOSTICS
About PATHWORK DIAGNOSTICS
Pathwork Diagnostics was a pioneering molecular diagnostics company focused on oncology, known for developing the Pathwork® Tissue of Origin Test. This innovative gene expression-based test was designed to assist physicians in identifying the primary site of difficult-to-diagnose tumors, including those that were poorly differentiated, undifferentiated, or metastatic. By analyzing a tumor’s genomic information through microarray-based RNA profiling, the test provided objective classification support when conventional pathology methods were insufficient.
The Pathwork Tissue of Origin Test utilized a proprietary informatics platform to compare the gene expression patterns of an uncertain tumor against a comprehensive database of known tumor types. This approach aimed to enhance diagnostic certainty, thereby enabling oncologists to make more informed, cancer-specific treatment decisions and potentially improve patient outcomes in precision oncology. The test was FDA-cleared as an in vitro diagnostic kit and was also available as a service through Pathwork’s CLIA-certified laboratory.
Pathwork Diagnostics was acquired by Response Genetics in August 2013. As of current information, the company is described as ‘deadpooled’ by some industry trackers, indicating it no longer operates as an independent entity. While not explicitly branded as an ‘AI company’ in the modern sense of deep learning, its reliance on advanced genomic analytics and proprietary informatics platforms for diagnostic insights represented a significant computational advancement in healthcare diagnostics at the time.
Focus Areas
Business Intelligence
| Key Investors | Abingworth, Advent Venture Partners, Alta Partners, Novus Ventures, Prospect Venture Partners, Venrock, Versant Ventures |
| Partnerships | Novartis (diagnostic discovery collaboration), Kindstar Diagnostics (distribution in China) |
| Acquisitions | Acquired Pathwork Informatics by Predicant Biosciences (2006); Assets acquired by Response Genetics (2013) |
| Technology | Microarray-based RNA profiling, Gene expression profiling, Proprietary analytics, Pathchip® microarray, Affymetrix GeneChip® System |
| FDA Clearances | 1 cleared products (estimated) |
What Physicians Need to Know
Pathwork Diagnostics stands out for physicians by providing crucial genomic insights that transform cancer care. The Pathworku00ae Tissue of Origin Test reduces diagnostic ambiguity for metastatic or poorly differentiated tumors, offering objective classification support when conventional pathology is insufficient. This enables oncologists to prescribe more appropriate, site-specific, and targeted therapies, potentially improving patient outcomes and avoiding the toxicities of less-specific treatments. The test increases physician confidence in treatment approaches and is practical for routine clinical use as it works on formalin-fixed, paraffin-embedded (FFPE) tissues, the most common clinical specimen type. It's available both as a service through their CLIA-certified laboratory and as an FDA-cleared in vitro diagnostic (IVD) kit for clinical laboratories.
The core technology relies on microarray-based RNA profiling, utilizing Pathwork Diagnostics' proprietary analytics and a companion Pathchipu00ae microarray. This Pathchipu00ae microarray runs on the proven Affymetrix GeneChipu00ae System. The test is available as a service through Pathwork's CLIA-certified laboratory and as an FDA-cleared in vitro diagnostic (IVD) kit for clinical laboratories to run themselves.
Reviews & Opinions
Videos
News, demos, and interviews about PATHWORK DIAGNOSTICS.
Videos load interactively. If none appear, search YouTube for PATHWORK DIAGNOSTICS →
Press & Coverage
Frequently Asked Questions
Related Companies
Clarista is a healthcare AI company that focuses on building a “trust layer” for enterprise AI, particularly within regulated industries like healthcare and financial services. The company’s platform aims to address the challenges of data fragmentation, governance, and compliance that often hinder the successful implementation of AI projects in large organizations. Clarista’s technology unifies structured […]
HelloBooks.ai is an AI-powered accounting software company that aims to automate and simplify financial management for small businesses, freelancers, and accounting professionals. The platform utilizes generative AI to handle repetitive bookkeeping tasks such as transaction categorization, receipt capture, bank reconciliation, and report generation. It is designed to reduce manual data entry and improve accuracy, allowing […]
Vero, also known as Vero.ai, is an artificial intelligence company specifically designed to augment clinical workflows and improve patient care within the healthcare sector. Their primary focus is on leveraging AI to streamline administrative tasks, enhance diagnostic accuracy, and personalize treatment plans. By automating routine processes, Vero aims to free up healthcare professionals’ time, allowing […]
Ant Group, a global digital technology provider and operator of Alipay, has significantly expanded its focus into healthcare AI. The company recently upgraded its physician platform, Haodf for Doctor, into ‘AQ for Doctor,’ an AI-powered workstation designed to support physicians across various stages of clinical practice, including online consultations, patient management, clinical decision support, and […]
e4health is a healthcare consulting and services company that provides innovative solutions to hospitals, health systems, outpatient providers, and physician practices. The company focuses on addressing data, quality, and revenue challenges within the healthcare ecosystem. Their services are designed to streamline health information data and workflows, optimize coding, quality, and clinical documentation integrity processes, and […]
PayZen is a healthcare AI company dedicated to solving the healthcare affordability crisis for both patients and providers. The company’s AI-powered platform offers personalized, interest-free, and fee-free patient financing solutions, enabling patients to manage their medical bills through affordable payment plans tailored to their unique ability to pay. This approach aims to increase access to […]